메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
저널정보
한국임상약학회 한국임상약학회지 한국임상약학회지 제15권 제1호
발행연도
2005.1
수록면
21 - 27 (7page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
A bioequivalence study of CKD Cefaclor ??capsule (Chong Kun Dang Pharm. Co., Ltd) to Ceclor??capsule (LillyKorea. Co., Ltd.) was conducted according to the guidelines of Korea Food and Drug Administration (KFDA). Twenty four healthy male Korean volunteers received each medicine at the cefaclor dose of 250 mg in a 2×2 crossover study. There was a one-week washout period between the doses. An improved high-performance liquid chromatography (HPLC) analytical method with UV detection was used to determine plasma cefaclor concentration in human volunteers for 8 hr after oral drug administration. The area under the plasma concentration-time curve from time zero to 8 hr (AUC0-8hr) was calculated by the linear trapezoidal rule. The Cmax (maximum plasma drug concentration) and Tmax (time to reach Cmax) were compiled from the plasma concentration-time data. Analysis of variance was carried out using logarithmically transformed AUC0-8hr and Cmax. No significant sequence effect was found for all of the bioavailability parameters indicating that the cross-over design was properly performed. The 90% confidence intervals of the AUC0-8hr ratio and the Cmax ratio for CKD Cefaclor ??and Ceclor?? were 0.9400≤δ≤1.0345 and 0.8858≤δ≤1.1021,respectively. These values were within the acceptable bioequivalence intervals of 0.80-1.25. Thus, our study demonstratedthe of CKD cefaclor??capsule was bioequivalent to Ceclor??capsule with respect to its bioavailability.

목차

등록된 정보가 없습니다.

참고문헌 (6)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0